Xin Lang Cai Jing·2025-11-01 01:49Core Points - Pfizer announced that the U.S. Federal Trade Commission has approved the early termination of the waiting period for its acquisition of Metsera, which is set to expire on November 7 [2] - Pfizer has filed a lawsuit against Metsera and its board, as well as Novo Nordisk, claiming breaches of contract and fiduciary duties due to Metsera's alleged violations of the merger agreement [3][4] - The lawsuit asserts that Novo Nordisk's proposal does not meet the criteria for a "Superior Company Proposal" and highlights significant regulatory risks associated with it [3][4] Summary by Sections Acquisition Approval - The FTC's approval allows Pfizer to proceed with the acquisition of Metsera without further regulatory delays, with all necessary approvals now in place [2] Legal Action - Pfizer's lawsuit claims that Metsera's board acted against their fiduciary duties by considering Novo Nordisk's proposal, which is characterized as an illegal attempt to suppress competition [3][4] - Pfizer seeks a temporary restraining order to prevent Metsera from terminating the merger agreement, asserting that the actions of Metsera and Novo Nordisk violate contractual and legal obligations [4] Regulatory Concerns - The lawsuit emphasizes that the structure of Novo Nordisk's proposal poses unacceptable regulatory risks, which Metsera's board previously acknowledged [4] - Pfizer expresses confidence in its case and aims to ensure the enforcement of the merger agreement's terms through appropriate legal remedies [4]